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Background: Desmoplastic small round cell tumour (DSRCT) is a rare sarcoma typically affecting young males and
usually widely metastatic at presentation. Despite multimodal treatment approaches, the prognosis for DSRCT is
extremely poor. Alkylator- and anthracyclines- based regimens are widely used as therapy and an initial response is
common. Durable responses are exceptionally rare so further systemic treatment options for these patients represent
an unmet medical need. We report two cases of metastatic, pretreated DSRCT patients achieving disease stabilisation
with Trabectedin.
Methods: Retrospective review of 2 patients with progressive DSRCT, treated with Trabectedin.
Results: Two males aged 19 and 23 years treated with Trabectedin, 1.5 mg/m2 over 24 hours 3 weekly for 6 and 5
cycles respectively. Best responses were stable disease in patient 1 and partial response (RECIST 1.1) in patient 2.
Progression free survival was 4 months in both cases. Persistent neutropenia required 4 weekly administration in one
patient but no other grade 3-4 toxicities occurred.
Conclusions: This report supports Trabectedin to be active and safe in pre-treated DSRCT patients. Further prospective
and collaborative efforts are desirable to better define its role in the management of this disease.
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DSRCT are an extremely rare mesenchymal malignancy,
with an estimated annual incidence rate of 0.1 case per
1.000.000. Nine out of ten cases occur in caucasian males
aged between 15 and 30 years [1]. DSRCT usually arise
and spread in the serosal surfaces (especially within the
peritoneal cavity), but can metastasize to the liver, ab-
dominal lymph nodes and lungs. Histologically, they are a
member of the family of small round blue cell tumors,
characterized by nests of small neoplastic cells surrounded
by a prominent desmoplastic stroma [2]. Molecular ana-
lysis plays a major role in the diagnosis of DSRCT: 96-97%
of all cases harbour a t(11;22) translocation, creating the
fusion of EWSR1 gene, on chromosome 22, with the WT1
gene, on chromosome 11 [3].
Due to the extreme rarity of this disease and the lack
of prospective studies, there is no consensus regarding
the best treatment approaches in DSRCT. DSRCT have* Correspondence: palma.dileo@uclh.nhs.uk
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unless otherwise stated.been reported to be sensitive to alkylator-based chemo-
therapy and, despite the absence of a defined standard,
aggressive approaches including attempted total macro-
scopic tumor excision combined with chemotherapy and
radiation are commonly used [4-7]. Prognosis remains
extremely poor and the identification of further treat-
ment options for DSRCT is an unmet medical need.Case presentation
This is the report of the clinical outcome of two patients
affected by DSRCT treated with Trabectedin at University
College of London Hospital. Data were retrospectively col-
lected and imaging was reviewed.Case 1
In May 2010 a 23-year-old male patient, with no signifi-
cant past medical history, presented with dysuria, low
abdominal pain and weight loss. Imaging, including a
CT scan of abdomen and pelvis showed a 12 cm large
lobulated mass arising from the retro-vescical space with
marked peritoneal disease and moderate ascites. Livertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Frezza et al. Clinical Sarcoma Research 2014, 4:3 Page 2 of 4
http://www.clinicalsarcomaresearch.com/content/4/1/3and pleural metastases were present. Biopsy of the pe-
ritoneal mass was consistent with DSRCT (desmin and
pan-cytokeratin positive; cromogranin, CD117, CD56,
S100, CK20, CK7, LCA and actin negative). Between
June 2010 and February 2011 he received 14 alternating
cycles of Vincristine, Cyclophosphamide, Doxorubicin and
Ifosfamide, Etoposide (VDC/IE), with a partial radiological
response. Exploratory laparoscopy was attempted in
March 2011, but no effective debulking was achievable.
Between March and July 2011 the patient received main-
tenance chemotherapy with Vincristine, Actinomycin D
and Cyclophosphamide (VAC), discontinued after 6 cycles
due to progressive disease. Between August and Septem-
ber 2011 he received treatment with Gemcitabine and Do-
cetaxel, discontinued after two cycles due to rapid clinical
progression (worsening of abdominal pain and shortness
of breath). With the view to control symptoms, he was
promptly started on Trabectedin 1.5 mg/m2 given as a 24
hours infusion every 3 weeks (cycle 1 in October 2011).
Treatment was tolerated with minimal side effects (grade
2 increase in creatin-phosphokinase). After three cycles
the patient reported an improvement in pain control and
breathlessness and a radiological stabilisation of disease.
Deterioration in symptoms and disease progression was
evident after 6 cycles and treatment was discontinued.
The patient died in May 2012.
Case 2
In September 2010 a 19-year-old boy presented with
shortness of breath, weight loss, abdominal pain and
marked cholestatic jaundice (bilirubin 240 umol/L). A
CT scan of abdomen and pelvis showed a large peritoneal
mass causing extrinsic compression of rectum, bladder
and the portal vein. The tumour caused liver infiltration
with hilar obstruction and marked dilatation of intra-
hepatic bile ducts. The abdominal mass extended into the
thorax through the foramen of Morgagni. A massive right
sided pleural effusion, pleural implants and multiple intra-
parenchymal and serosal liver metastases were reported.
The large peritoneal mass was biopsied and pathology was
found to be consistent with intrabdominal DSRCT (des-
min positive, cytokeratine, NSE, calretinin, S100, LCA and
WT1 negative).
He underwent a therapeutic endoscopic retrograde cho-
langiopancreatography with stent insertion, pleural effu-
sion drainage and was started on VDC/IE. He completed
14 cycles in March 2011 reporting minimal side effects
and achieving a major radiological response and symp-
tomatic relieve with resolution of pain. Between May 2011
and May 2012 he received 12 cycles of VAC before dis-
continuation at the patient request. In August 2012 he
became unwell with marked disease progression and
commenced Trabectedin. Treatment was well tolerated
with minimal side effects including a grade 1 nausea,grade 2 alkaline phosphatase (437 IU/L) and grade 3
neutropenia (800/mL). A restaging assessment performed
in November 2012 after 3 cycles of Trabectedin showed a
reduction in size of the nodule deep to the xiphisternum
(5 × 2.5 cm) and a significant reduction of the omental
disease associated with minimal free fluid in the abdomen
and pelvis (Figure 1). Given the radiological response, the
patient received two further cycles of Trabectedin, switch-
ing to a 4 weekly schedule in view of persistent myelosup-
pression before disease progression. In November 2012.
He failed to benefit from oral cyclophosphamide and
prednisolone, dying of disease in January 2013.
Conclusions
Trabectedin is a marine-derived antineoplastic agent,
initially isolated from the tunicate Ecteinascidia turbi-
nata and now produced synthetically, which is currently
approved in Europe for the treatment of advanced soft
tissue sarcoma after prior treatment with an anthracycline.
The first phase II studies were conducted in metastatic
leiomyosarcoma and liposarcoma. Myxoid liposarcoma
(MLS), a subtype characterised by the expression of the
oncogenic transcript FUS/CHOP, has been shown to be
extremely sensitive to Trabectedin, with a reported overall
response rate of 50% and a median PFS of 17 months [8].
Trabectedin exerts its activity in MLS not only through a
direct growth inhibition, but also by affecting the tumour
microenvironment and inducing maturation of MLS lipo-
blasts by targeting the FUS/CHOP-mediated transcrip-
tional block [9,10]. Grohar et al. reported on Trabectedin
interfering with the activity of EWS-FLI1 in Ewing sar-
coma cells [11]. Activity has been reported in patients
with metastatic synovial sarcoma [12], alveolar soft part
sarcoma, and endometrial stromal sarcoma. On the basis
of Trabectedin activity in translocation related sarcoma, a
phase III randomised trial in first-line to compare Trabec-
tedin with doxorubicin-based chemotherapy was initiated
and results are awaited.
The potential efficacy of Trabectedin in DSRCT was
first postulated by Lopez-Gonzalez A. et al., reporting
the case of a patient achieving a partial response with 3-
weekly Trabectedin as a third line treatment [13]. More
recently, a DSRCT patient treated in the context of a
phase I and pharmacokinetic study of Trabectedin in
children and adolescents reported stable disease for 6 cy-
cles. The same study showed how Trabectedin, 1.5 mg/m2
given as a 24 hour infusion every 3 weeks is safe in adoles-
cents, the toxicity profile being similar to that reported for
adults (myelosuppression, elevated serum transaminases,
fatigue, nausea and emesis) [14].
In this report we confirmed that Trabectedin can be
safely administered in heavily pretreated DSRCT patients,
and may provide valuable control of symptoms, albeit
temporarily, with radiological stabilization and regression
Figure 1 Activity of Trabectedin in DSRCT. Reduction in size of a nodule deep to the xiphisternum (A and B) and significant reduction of the
omental disease (C and D) after three cycles of Trabectedin in case 2.
Figure 2 Institutional standard approach for DSRCT. Fourteen cycles of interval compressed VDC/IE are administered, with surgery performed
at best response (after 4-6 cycles) if complete resection is anticipated. Patients who are not suitable for surgery undergo a maintenance treatment
with VAC up to progression or unacceptable toxicity. At time of progression, a single agent treatment with Trabectedin or Pazopanib is
considered [15].
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managed through schedule adjustment without the need
for dose reduction. Our results together with data avail-
able in literature suggest that Trabectedin is a potentially
active treatment option for DSRCT patients and therefore
could be considered as a possible further line of treatment
at the time of progression after standard regimens.
To date, no specific evidence-based consensus guide-
lines have been published for the management of DSRCT.
The treatment strategy in our institution is shown in
Figure 2 and can provide the basis for prospective evalu-
ation of new approaches and new agents [15]. In view of
the rarity of DSRCT and the lack of improvement in out-
come, we believe that multi-institutional prospective stu-
dies should be promoted to identify better therapeutic
approaches including assessment of the value of agents
such as Trabectedin.
Consent
Since both patients died at the time of data review and
publication, no written consensus could be obtained.
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